From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis

Clin Genitourin Cancer. 2017 Oct;15(5):509-512.e9. doi: 10.1016/j.clgc.2017.04.008. Epub 2017 Apr 13.

Authors

Andrea Necchi¹, Daniele Raggi², Patrizia Giannatempo², Guru Sonpavde³, Matthew D Galsky⁴, Joaquim Bellmunt⁵, Luigi Mariani², Rosalba Miceli²

Affiliations

¹ Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: andrea.necchi@istitutotumori.mi.it.
² Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
³ University of Alabama Comprehensive Cancer Center, Birmingham, AL.
⁴ Mount Sinai School of Medicine, Tisch Cancer Institute, New York, NY.
⁵ Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

PMID: 28478885
DOI: 10.1016/j.clgc.2017.04.008

No abstract available

Keywords: Bladder cancer; Immunotherapy; Meta-analysis; Salvage therapy; Urothelial carcinoma.

Publication types

Comparative Study
Historical Article
Meta-Analysis

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / metabolism
Clinical Trials as Topic
History, 21st Century
Humans
Immunotherapy / history*
Immunotherapy / methods
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / metabolism
Salvage Therapy
Survival Analysis
Treatment Outcome
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / metabolism

Substances

Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
PDCD1 protein, human
Programmed Cell Death 1 Receptor